| Literature DB >> 32948829 |
Shun Koyamaishi1, Takuya Kamio1, Akie Kobayashi1, Tomohiko Sato1, Ko Kudo1, Shinya Sasaki1, Rika Kanezaki1, Daiichiro Hasegawa2, Hideki Muramatsu3, Yoshiyuki Takahashi3, Yoji Sasahara4, Hidefumi Hiramatsu5, Harumi Kakuda6, Miyuki Tanaka7, Masataka Ishimura8, Masanori Nishi9, Akira Ishiguro10, Hiromasa Yabe11, Takeo Sarashina12, Masaki Yamamoto13, Yuki Yuza14, Nobuyuki Hyakuna15, Kenichi Yoshida16, Hitoshi Kanno17, Shouichi Ohga8, Akira Ohara18, Seiji Kojima3, Satoru Miyano19, Seishi Ogawa16,20,21, Tsutomu Toki1, Kiminori Terui1, Etsuro Ito22.
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of Diamond-Blackfan anemia (DBA). However, data regarding the optimal conditioning regimen for DBA patients are limited. We retrospectively compared the outcomes of DBA patients who underwent HSCT using either myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) regimens. The patients belonged to a cohort treated at our hospitals between 2000 and 2018. HSCT was performed in 27 of 165 patients (16.4%). The median age at the time of HSCT was 3.6 years. Stem cell sources included bone marrow for 25 patients (HLA-matched sibling donors, n = 5; HLA-mismatched related donors, n = 2; HLA-matched/mismatched unrelated donors, n = 18) or cord blood for 2 patients. MAC or RIC regimens were used in 12 and 15 patients, respectively. Engraftment was successful in all 27 patients who underwent HSCT. Three patients who underwent HSCT using MAC regimens developed sinusoidal obstruction syndrome. The 3-year overall survival (OS) and failure-free survival rates (FFS) post-transplantations were 95.2% and 88.4%, respectively, with no significant differences between MAC and RIC regimens. Our data suggest that HSCTs using RIC regimens are effective and obtain engraftment with excellent OS and FFS for young DBA patients.Entities:
Mesh:
Year: 2020 PMID: 32948829 DOI: 10.1038/s41409-020-01056-1
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483